STING agonist 22 is a novel, non-nucleotide specific small-molecule STING agonist with IC50 of 28, 11 uM for human STING isoforms WT and HAQ, respectively.STING agonist 22 did not show any cytotoxicity in an immune cell proliferation panel across a variety of immune cell types and also did not show any activity in a kinome panel.STING agonist 22 introduced higher levels of iFIT3 and MX1 mRNA across three different donors possessing different STING genotypes: WT/WT, WT/HAQ, and WT/R232H in human PBMCs (IC50=5-35 uM).STING agonist 22 demonstrated in vivo antitumor effect in an MC38 mice model, with STING pathway activation and production of type I IFNs and proinflammatory cytokines, serum levels of IL-6, G-SCF, and MIP-1β.

STING agonist-8 is a potent STING agonist with an EC50 of 27 nM in THP1-Dual KI-hSTING-R232 cells (WO2021239068A1, compound 5-AB).

IACS-8779 disodium is a highly potent stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy. IACS-8779 disodium shows robust activation of the STING pathway in vitro and a superior systemic anti-tumor response in the B16 murine model of melanoma.

Bis-(3'-5')-cyclic dimeric adenosine monophosphate (c-di-AMP) is a bacterial second messenger implicated in the control of cell wall metabolism, osmotic stress responses and sporulation. Detection of c-di-AMP by the host cytoplasmic surveillance pathway (CSP) is known to elicit type I IFN responses through a signaling axis that involves STING, TBK1 and IRF3 [1, 2]. Involvement of the helicase DDX41 in the recognition of c-di-AMP has been suggested [3]. Recent studies have also demonstrated that c-di-AMP exerts strong adjuvant activities when delivered by the mucosal route [4, 5].

Cyclic di-GMP (c-di-GMP) is one of the most important and common bacterial second messenger. It is involved in numerous prokaryotic processes, including biofilm formation, motility, virulence, and cell cycling. c-di-GMP also has functions in eukaryotic cells. It is detected by the transmembrane protein stimulator of interferon genes (STING), leading to activation of the innate immune system.

STING agonist-3, compound 3, is a selective and non-nucleotide small-molecule STING agonist, which has durable anti-tumor effect and tremendous potential to improve treatment of cancer.

diABZI STING agonist-1 (trihydrochloride) is a selective stimulator of interferon genes (STING) receptor agonist.

STING agonist C11 is an agonist of the stimulator of interferon genes (STING) pathway.

MSA-2 analogue is an orally available human STING agonist.

STING agonist 4 is an amidobenzimidazole (ABZI)-based compound that functions as a STING agonist with Kd of 1.6 nM (binding of endogenous full-length STING, THP-1 cell lysates); caused dose-dependent phosphorylation of IRF3 and STING that was inhibited by the TBK1 inhibitor BX795, induced dose-dependent secretion of IFN-β with EC50 of 3.1 uM in PBMCs (18-fold more potent than cGAMP); promotes production of IFN-γ-induced protein 10 (IP-10), IL-6 and TNFα by a mechanism that is dependent on STING-mediated activation of TBK1; unlike cGAMP and DMXAA, compound 2 efficiently activates STING function while maintaining an open STING confirmation.

SN-008, a less active SN-011 analog, can be used as a negative control.

Cridanimod sodium is a potent type I interferon (IFN) inducer that directly binds to STING and triggers a strong antiviral response through the TBK1/IRF3 route.

Cyclic di-GMP (c-di-GMP) disodium is a STING activator and a global bacterial second messenger, which regulates biofilm formation, motility, and virulence in diverse bacterial species.

IACS-8803 diammonium is a highly potent cyclic dinucleotide STING agonist. IACS-8803 diammonium has a robust systemic antitumor efficacy.

Cyclic di-GMP (c-di-GMP) diammonium is a STING activator and a global bacterial second messenger, which regulates biofilm formation, motility, and virulence in diverse bacterial species.

E7766 disodium is a macrocycle-bridged STING agonist with a Kd of 40 nM. E7766 disodium shows potent pan-genotypic and antitumor activities.

STING agonist-3 trihydrochloride, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule STING agonist with a pEC50 and pEC50 of 7.5 and 9.5, respectively. STING agonist-3 trihydrochloride has durable anti-tumor effect and tremendous potential to improve treatment of cancer.

E7766 diammonium salt is a macrocycle-bridged STING agonist with a Kd of 40 nM. E7766 diammonium salt shows potent pan-genotypic and antitumor activities.

IACS-8803 disodium is a highly potent cyclic dinucleotide STING agonist. IACS-8803 disodium has a robust systemic antitumor efficacy.

STING ligand-1 is a lead STING ligand with an IC50 of 68 nM for HAQ STING.

Cyclic di-GMP sodium (c-di-GMP sodium) is a STING activator and a global bacterial second messenger, which regulates biofilm formation, motility, and virulence in diverse bacterial species.

STING agonist compound 17 is a selective stimulator of interferon genes (STING) receptor agonist.

STING CDN agonist IFM Therapeutics is a synthetic cyclic dinucleotide (CDN) agonist of STING, stimulates potent immunity against cancer..

SINCRO is a novel anti-cancer compound that can activate the cytosolic DNA-sensing STING signaling pathway leading to the induction of type I interferon (IFN) genes.